Hyperprogression with immunotherapy: Is it real?

Sanjay Popat^{1

2

3}

Affiliations

¹ Department of Medicine, Royal Marsden Hospital, London, United Kingdom.
² Genomic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
³ Thoracic Oncology, Institute of Cancer Research, London, United Kingdom.

Free article

Editorial

Sanjay Popat. Cancer. 2019.

Free article

. 2019 Apr 15;125(8):1218-1220.

doi: 10.1002/cncr.31997. Epub 2019 Feb 15.

Sanjay Popat^{1

2

3}

¹ Department of Medicine, Royal Marsden Hospital, London, United Kingdom.
² Genomic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
³ Thoracic Oncology, Institute of Cancer Research, London, United Kingdom.

No abstract available

Keywords: NSCLC; checkpoint inhibitor; hyperprogression; immunotherapy; progression.

Comment on

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL. Kanjanapan Y, et al. Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15. Cancer. 2019. PMID: 30768786